Flurbiprofen Dosage

Medically reviewed by Drugs.com. Last updated on Aug 2, 2023.

Applies to the following strengths: 50 mg; 100 mg

Usual Adult Dose for Osteoarthritis

200 mg to 300 mg orally per day in 2 to 4 divided doses
Maximum single dose: 100 mg

Comments:

Once response to therapy is determined, dose and frequency should be adjusted to the lowest effective dose for the shortest duration possible to suit individual patient treatment goals.

Uses: For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis

200 mg to 300 mg orally per day in 2 to 4 divided doses
Maximum single dose: 100 mg

Comments:

Once response to therapy is determined, dose and frequency should be adjusted to the lowest effective dose for the shortest duration possible to suit individual patient treatment goals.

Uses: For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis

Advanced Renal Disease: Not recommended; if treatment is necessary, close monitoring of renal function is advised.

Dosage adjustments may be required in hepatic disease; however, no specific guidelines have been suggested. Caution recommended.

Patients who have an abnormal liver test or who develop signs or symptoms of liver dysfunction should be evaluated for hepatic dysfunction.
If liver disease develops or if systemic manifestations such as eosinophilia or rash occur, this drug should be discontinued.

Elderly: Elderly patients may require lower doses due to increased risk for adverse effects and increased likelihood of concomitant hepatic and/or renal impairment.

US BOXED WARNINGS: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS:

Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.
This drug is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Data not available

Administration advice:

General:

Prior to initiating treatment, the potential benefits and risks of this drug should be weighed against other treatment options.
The lowest effective dose for the shortest duration consistent with individual patient treatment goals should be used.
There is an increased risk of heart attack, heart failure, and stroke when taking nonsteroidal anti-inflammatory drugs (NSAIDs); these events may occur at any time during treatment and risk increases with long term use, a history of cardiovascular (CV) disease or risk factors for CV disease, and higher doses.

Monitoring:

Cardiovascular: Monitor blood pressure closely during initiation and throughout course of therapy.
Gastrointestinal: Monitor for signs/symptoms of gastrointestinal bleeding.
Renal function: Monitor renal status, especially in patients with conditions where renal prostaglandins have a supportive role in the maintenance of renal perfusion.
Monitor blood counts, renal, and hepatic function periodically for patients receiving long-term therapy.

Patient advice:

Patients should seek medical advice for signs and symptoms of gastrointestinal events, adverse skin reactions, allergic reactions, hepatotoxicity, or unexplained weight gain or edema.
Patients should seek medical attention immediately if signs/symptoms of cardiovascular events occur including, shortness of breath, slurred speech, chest pain, or weakness on one side of the body.
Patients should talk to their health care provider if they are pregnant, planning to become pregnant, or breastfeeding; NSAIDs should not be used at 20 weeks or later in pregnancy unless specifically advised to do so by their health care professional.